Chinnapong/iStock via Getty Images
If you were invested in Medical Properties Trust (NYSE:MPW) toward the end of 2021, when the stock was selling for a little over $24 per share and then look at its recent price level of under $12 per
Medical Properties Trust: A Decent Total Return Can Reasonably Be Expected
Summary
- Medical Properties Trust's share price is not the bottomless pit envisioned by short sellers.
- Nor, in the present macro environment, is the share price likely to return anywhere near its previous high.
- Understanding what one can reasonably expect in the near to mid-term requires an evaluation of both macroeconomic forces and MPW idiosyncratic factors.
- Within the context of a diversified portfolio, MPW's risk/reward profile maps well to a probable scenario that would make it a reasonable investment.
I am a retiree who has spent the last six years reading about economics, financial systems, and individual investment strategies and companies. My primary background is as a senior executive in government, working for the Department of Defense as a planner and financial manager. I have also worked in industry, running a business development unit, and have attended the Harvard Program for Management Development.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of MPW either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.